Table 3 Prognostic factors for overall mortality in patients with IPF assessed by using Cox regression analysis.

From: Impact of the revised definition on incidence and outcomes of acute exacerbation of idiopathic pulmonary fibrosis

Variables

Unadjusted

Multivariable

HR

95% CI

P value

HR

95% CI

P value

Age

1.040

1.021–1.060

< 0.001

1.028

1.005–1.052

0.018

Male gender

0.984

0.713–1.360

0.924

   

BMI

0.908

0.865–0.953

< 0.001

0.944

0.894–0.997

0.037

Charlson comorbidity index

1.130

1.018–1.255

0.022

–

–

–

Ever smoker

0.957

0.706–1.297

0.777

   

FVC, % pred

0.946

0.937–0.956

< 0.001

0.974

0.961–0.987

< 0.001

DLco, % pred

0.951

0.943–0.960

< 0.001

0.987

0.973–1.001

0.066

6MWT distance

0.994

0.993–0.996

< 0.001

0.998

0.997–1.000

0.038

6MWT resting SpO2

0.791

0.728–0.858

< 0.001

–

–

–

6MWT lowest SpO2

0.968

0.960–0.976

< 0.001

0.973

0.957–0.990

0.002

Disease progressiona

3.043

2.169–4.267

< 0.001

2.269

1.568–3.283

< 0.001

AEb

3.250

2.387–4.425

< 0.001

1.740

1.220–2.481

0.002

Steroid ± IM

1.057

0.767–1.457

0.734

   
  1. IPF idiopathic pulmonary fibrosis, HR hazard ratio, CI confidence interval, BMI body mass index, FVC forced vital capacity, DLco diffuse lung capacity of carbon monoxide, 6MWT 6-min walk test, SpO2 saturation of pulse oximetry, AE acute exacerbation, IM immunosuppressant.
  2. aDisease progression was defined as 10% relative decline in FVC for 6 months.
  3. bAE was compared to no respiratory deterioration in Cox regression analysis.
Back to article page